Collection of Endometrial Cancer-derived Organoids to Evaluate the Efficacy of PARP Inhibitors: PENDOR Pilot Study

Inclusion Criteria: * Patient aged 18 years or more * Patient with histologically confirmed, localized endometrial cancer, candidate for surgical treatment. * Patient with localized endometrial cancer, presenting: * A high-grade endometrioid histological type and/or * P53 mutation and/or * a non-endometrioid histological type regardless of P53 status. * Patient affiliated to a social security scheme * Information and signature of informed consent prior to any specific study procedure Exclusion Criteria: * Other active cancer less than 6 months old (with the exception of treated basal cell carcinoma of the skin). * Patient deprived of liberty, under guardianship, or subject to a legal protection measure, or unable to express consent.